UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
Belgium’s largest drugmaker UCB (Euronext: UCB) today announced positive data from studies involving its investigational ...
Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for ...
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...
The Bruins welcomed Caelan Rawson-Turner to TD Garden on Saturday as part of a special event through the Make-A-Wish ...
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...
Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
Fintel on MSN2d
Leerink Partners Initiates Coverage of Nurix Therapeutics (NRIX) with Market Perform RecommendationFintel reports that on March 17, 2025, Leerink Partners initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback